More enthusiasm for ADCs as Boehringer buys NBE, gaining conjugate platform

Weeks after Merck & Co.’s multibillion dollar takeout of VelosBio, Boehringer believes its purchase of NBE in a smaller deal will give it an earlier-stage, best-in-class product against the same target.

Boehringer Ingelheim GmbH will acquire NBE-Therapeutics AG in a deal worth up to €1.2 billion ($1.4 billion), including milestones. The parties aren’t disclosing how much Boehringer is paying up front, NBE CEO Bertrand Damour told BioCentury...